GENITAL WARTS TREATMENT MARKET ANALYSIS

Genital Warts Treatment Market, By Drug Type (Imiquimod, Podophyllin and Podofilox, Trichloroacetic Acid, Sinecatechins, Others), By Route of Administration (Parenteral and Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In December 2023, Padagis, a pharmaceutical company, has received U.S. FDA approval to market Podofilox Gel, the first generic version of CondyloxGel, 0.5%, in the United States. Podofilox Gel is an antimitotic medication used topically for treating anogenital warts, including external genital warts and perianal warts.
In January 2023, Verrica Pharmaceuticals, a pharmaceutical company, announced that it received the meeting minutes from its recent Type C meeting with the FDA, held on November 6, 2023. The meeting focused on discussing the Phase 3 clinical development plan for YCANTH for the treatment of common warts. Verrica believes the meeting successfully addressed its objectives to gain FDA advice and agreement on the pivotal Phase 3 study design necessary to support an efficacy supplement for this new indication. Currently approved for molluscum contagiosum, YCANTH aims to expand its therapeutic use pending further clinical trials.